Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2019

Open Access 01-03-2019 | Colorectal Cancer | HEPATOBILIARY TUMORS

The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy

Authors: D. Pereyra, B. Rumpf, M. Ammann, MD, S. F. Perrodin, MD, D. Tamandl, MD, C. Haselmann, J. Stift, MD, C. Brostjan, PhD, F. Laengle, MD, G. Beldi, MD, T. Gruenberger, MD, P. Starlinger, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2019

Login to get access

Abstract

Background

Neoadjuvant chemotherapy (NeoCTx) is performed for most patients with colorectal cancer liver metastases (CRCLM). However, chemotherapy-associated liver injury (CALI) has been associated with poor postoperative outcome. To date, however, no clinically applicable and noninvasive tool exists to assess CALI before liver resection.

Methods

Routine blood parameters were assessed in 339 patients before and after completion of NeoCTx and before surgery. The study assessed the prognostic potential of the aspartate aminotransferase (AST)-to-platelet ratio index (APRI), the albumin-bilirubin grade (ALBI), and their combinations. Furthermore, an independent multi-center validation cohort (n = 161) was included to confirm the findings concerning the prediction of postoperative outcome.

Results

Higher ALBI, APRI, and APRI + ALBI were found in patients with postoperative morbidity (P = 0.001, P = 0.064, P = 0.001, respectively), liver dysfunction (LD) (P = 0.009, P = 0.012, P < 0.001), or mortality (P = 0.037, P = 0.045, P = 0.016), and APRI + ALBI had the highest predictive potential for LD (area under the curve [AUC], 0.695). An increase in APRI + ALBI was observed during NeoCTx (P < 0.001). Patients with longer periods between NeoCTx and surgery showed a greater decrease in APRI + ALBI (P = 0.006) and a trend for decreased CALI at surgery. A cutoff for APRI + ALBI at − 2.46 before surgery was found to identify patients with CALI (P = 0.002) and patients at risk for a prolonged hospital stay (P = 0.001), intensive care (P < 0.001), morbidity (P < 0.001), LD (P < 0.001), and mortality (P = 0.021). Importantly, the study was able to confirm the predictive potential of APRI + ALBI for postoperative LD and mortality in a multicenter validation cohort.

Conclusion

Determination of APRI + ALBI before surgery enables identification of high-risk patients for liver resection. The combined score seems to dynamically reflect CALI. Thus, APRI + ALBI could be a clinically relevant tool for optimizing timing of surgery in CRCLM patients after NeoCTx.
Appendix
Available only for authorised users
Literature
1.
Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.CrossRefPubMedPubMedCentral
2.
Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406; discussion 406–7.CrossRefPubMedPubMedCentral
3.
Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Onco. 2015;26:702–8.CrossRef
4.
Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.CrossRefPubMed
5.
Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225–39.CrossRefPubMedPubMedCentral
6.
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet London Engl 2008;371:1007–16.CrossRef
7.
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.CrossRefPubMed
8.
Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009;16:2385–90.CrossRefPubMed
9.
Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94:274–86.CrossRefPubMed
10.
Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.CrossRefPubMed
11.
Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:421–30.CrossRefPubMed
12.
Zhao J, van Mierlo KMC, Gomez-Ramirez J, et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104:990–1002.CrossRefPubMed
13.
Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983–90.CrossRefPubMed
14.
Vigano L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258:731–40; discussion 741–2.CrossRefPubMed
15.
Wolf PS, Park JO, Bao F, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single-institution experience. J Am Coll Surg. 2013;216:41–9.CrossRefPubMed
16.
Abdalla EK, Vauthey JN. Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful? Dig Surg. 2008;25:421–9.CrossRefPubMed
17.
Welsh FK, Tekkis PP, John TG, Rees M. Predictive models in colorectal liver metastases: can we personalize treatment and outcome? Dig Surg. 2008;25:406–12.CrossRefPubMed
18.
Pinato DJ, Yen C, Bettinger D, et al. The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. Alimentary Pharmacol Therapeutics. 2017;45:714–22.CrossRef
19.
Hiraoka A, Kumada T, Hirooka M, et al. A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: usefulness of albumin-bilirubin grade. Hepatol Res. 2017;48:61–7.CrossRef
20.
Cheung RC, Currie S, Shen H, et al. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol. 2008;42:827–34.CrossRefPubMed
21.
Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012;12:14.CrossRefPubMedPubMedCentral
22.
Oh IS, Sinn DH, Kang TW, et al. Liver function assessment using albumin-bilirubin grade for patients with very early-stage hepatocellular carcinoma treated with radiofrequency ablation. Dig Dis Scis. 2017;62:3235–42.CrossRef
23.
Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782–9.e784.
24.
Singh A, Le P, Peerzada MM, Lopez R, Alkhouri N. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 2 diabetic patients. J Clin Gastroenterol. 2017;52:268–72.
25.
Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure. Medicine. 2017;96:e7142.CrossRefPubMedPubMedCentral
26.
Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology Baltimore. 2011;53:726–36.CrossRef
27.
Toniutto P, Fabris C, Bitetto D, et al. Role of AST-to-platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol. 2007;22:1904–8.CrossRefPubMed
28.
Wang L, Feng Y, Ma X, et al. Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis. PloS One. 2017;12:e0182969.CrossRefPubMedPubMedCentral
29.
Park S, Kim HY, Kim H, et al. Changes in noninvasive liver fibrosis indices and spleen size during chemotherapy: potential markers for oxaliplatin-induced sinusoidal obstruction syndrome. Medicine. 2016;95:e2454.CrossRefPubMedPubMedCentral
30.
Soubrane O, Brouquet A, Zalinski S, et al. Predicting high-grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251:454–60.CrossRefPubMed
31.
Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66:338–46.CrossRefPubMed
32.
Chen RC, Cai YJ, Wu JM, et al. Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis. J Viral Hepatitis. 2017;24:238–45.CrossRef
33.
Zou H, Wen Y, Yuan K, Miao XY, Xiong L, Liu KJ. Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients. Liver Int. 2017;38:494–502.CrossRefPubMed
34.
Ratti F, Cipriani F, Catena M, Paganelli M, Aldrighetti L. Liver failure in patients treated with chemotherapy for colorectal liver metastases: role of chronic disease scores in patients undergoing major liver surgery: a case-matched analysis. Eur J Surg Oncol. 2014;40:1550–6.CrossRefPubMed
35.
Tanaka S, Iimuro Y, Hirano T, Hai S, Suzumura K, Fujimoto J. Prediction of postoperative hepatic failure after liver resection for hepatocellular carcinoma: significance of the aspartate aminotransferase-to-platelet ratio index. Hepatogastroenterology. 2014;61:755–61.PubMed
36.
Cheng J, Zhao P, Liu J, Liu X, Wu X. Preoperative aspartate aminotransferase-to-platelet ratio index (APRI) is a predictor on postoperative outcomes of hepatocellular carcinoma. Medicine. 2016;95:e5486.CrossRefPubMedPubMedCentral
37.
Wang YY, Zhong JH, Su ZY, et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016;103:725–34.CrossRefPubMed
38.
Ichikawa T, Uenishi T, Takemura S, et al. A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma. J Hepato-Biliary-Pancreatic Surg. 2009;16:42–8.CrossRef
39.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology Baltimore. 2005;41:1313–21.CrossRef
40.
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed
41.
Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3:e170278.CrossRefPubMedPubMedCentral
42.
Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol. 2017;72:521–33.CrossRefPubMed
43.
Krieger PM, Tamandl D, Herberger B, et al. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol. 2011;18:1644–50.CrossRefPubMed
44.
Russolillo N, Langella S, Perotti S, Lo Tesoriere R, Forchino F, Ferrero A. Preoperative assessment of chemotherapeutic associated liver injury based on indocyanine green retention test. Int J Surg London Engl. 2016;31:80–5.CrossRef
45.
Viganò L, Ravarino N, Ferrero A, Motta M, Torchio B, Capussotti L. Prospective evaluation of accuracy of liver biopsy findings in the identification of chemotherapy-associated liver injuries. Arch Surg Chicago. 2012;147:1085–91.CrossRefPubMed
46.
Vigano L, De Rosa G, Toso C, et al. Reversibility of chemotherapy-related liver injury. J Hepatol. 2017;67:84–91.CrossRefPubMed
Metadata
Title
The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy
Authors
D. Pereyra
B. Rumpf
M. Ammann, MD
S. F. Perrodin, MD
D. Tamandl, MD
C. Haselmann
J. Stift, MD
C. Brostjan, PhD
F. Laengle, MD
G. Beldi, MD
T. Gruenberger, MD
P. Starlinger, MD, PhD
Publication date
01-03-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-07125-6

Other articles of this Issue 3/2019

Annals of Surgical Oncology 3/2019 Go to the issue

Thoracic Oncology

Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients

Thoracic Oncology

Does Complete Pathologic Response Come to Those Who Wait?

PANCREATIC TUMORS

The Value of International Collaboration in Pancreatic Cancer Research: EURECCA

Health Services Research and Global Oncology

Impact of Long-Course Neoadjuvant Radiation on Postoperative Low Anterior Resection Syndrome and Quality of Life in Rectal Cancer: Post Hoc Analysis of a Randomized Controlled Trial

Health Services Research and Global Oncology

Lessons Learned Regarding Missing Clinical Stage in the National Cancer Database

Health Services Research and Global Oncology

What’s Lost in What’s Missing: A Thoughtful Approach to Missing Data in the National Cancer Database